PF-AtlasClinical Trials › NCT05389215

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

DWN12088 · Phase 2

Registry ID
NCT05389215
Phase
Phase 2
Status
Recruiting
Drug / intervention
DWN12088
Sponsor
Daewoong Pharmaceutical Co. LTD.
Start
2022-07-29

About this trial

DWN12088 is evaluated in NCT05389215, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Daewoong Pharmaceutical Co. LTD.. Current status: Recruiting.

View NCT05389215 on ClinicalTrials.gov →

Explore related

Related trials

Medical disclaimer. This page summarizes public trial data for NCT05389215 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.